Junkins-Hopkins JM - Search Results

1

Mycosis fungoides and sezary syndrome: an update.

Kim EJ, Lin J, Junkins-Hopkins JM, Vittorio CC, Rook AH. Kim EJ, et al. Curr Oncol Rep. 2006 Sep;8(5):376-86. doi: 10.1007/s11912-006-0061-1. Curr Oncol Rep. 2006. PMID: 16901399 Review.

2

High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome.

Richardson SK, Lin JH, Vittorio CC, Kim EJ, Yoon JS, Junkins-Hopkins J, Rook AH. Richardson SK, et al. Clin Lymphoma Myeloma. 2006 Nov;7(3):226-32. doi: 10.3816/CLM.2006.n.063. Clin Lymphoma Myeloma. 2006. PMID: 17229339 Clinical Trial.

3

Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome.

Introcaso CE, Micaily B, Richardson SK, Junkins-Hopkins JM, Yoon JS, Kim EJ, Vittorio CC, Rook AH. Introcaso CE, et al. J Am Acad Dermatol. 2008 Apr;58(4):592-5. doi: 10.1016/j.jaad.2007.12.016. Epub 2008 Feb 4. J Am Acad Dermatol. 2008. PMID: 18249469

4

Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma.

Gormley RH, Hess SD, Anand D, Junkins-Hopkins J, Rook AH, Kim EJ. Gormley RH, et al. J Am Acad Dermatol. 2010 Feb;62(2):300-7. doi: 10.1016/j.jaad.2009.02.035. Epub 2009 Nov 26. J Am Acad Dermatol. 2010. PMID: 19944484 Review.

5

Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.

McGinnis KS, Junkins-Hopkins JM, Crawford G, Shapiro M, Rook AH, Vittorio CC. McGinnis KS, et al. J Am Acad Dermatol. 2004 Mar;50(3):375-9. doi: 10.1016/j.jaad.2003.10.669. J Am Acad Dermatol. 2004. PMID: 14988678

6

Low-dose bexarotene and low-dose interferon alfa-2b for adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus 1.

Richardson S, Budgin JB, Junkins-Hopkins JM, Vittorio CC, Lee J, Miller WT Jr, Rook AH, Kim EJ. Richardson S, et al. Arch Dermatol. 2005 Mar;141(3):301-4. doi: 10.1001/archderm.141.3.301. Arch Dermatol. 2005. PMID: 15781670 No abstract available.

7

Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, Rook AH. Kim EJ, et al. J Clin Invest. 2005 Apr;115(4):798-812. doi: 10.1172/JCI24826. J Clin Invest. 2005. PMID: 15841167 Free PMC article. Review.

8

Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.

Avarbock AB, Loren AW, Park JY, Junkins-Hopkins JM, Choi J, Litzky LA, Rook AH. Avarbock AB, et al. Am J Hematol. 2008 Jul;83(7):593-5. doi: 10.1002/ajh.21180. Am J Hematol. 2008. PMID: 18335564 Free article.

9

CD8+ epidermotropic cytotoxic T-cell lymphoma with peripheral blood and central nervous system involvement.

Introcaso CE, Kim EJ, Gardner J, Junkins-Hopkins JM, Vittorio CC, Rook AH. Introcaso CE, et al. Arch Dermatol. 2008 Aug;144(8):1027-9. doi: 10.1001/archderm.144.8.1027. Arch Dermatol. 2008. PMID: 18711076

10

Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Olsen EA, et al. J Am Acad Dermatol. 2011 Feb;64(2):352-404. doi: 10.1016/j.jaad.2010.08.037. Epub 2010 Dec 9. J Am Acad Dermatol. 2011. PMID: 21145619 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

109 results

Search Page